|
Mark B. McClellan, M.D., Ph.D
11/14/2002 - 3/26/2004*
Mark McClellan was sworn in as Commissioner of Food and Drugs on
November 14, 2002, following Senate confirmation by unanimous consent.
Previously, he was Associate Professor of Economics at Stanford
University, Associate Professor of Medicine at Stanford Medical
School, a practicing internist, and Director of the Program on Health
Outcomes Research at Stanford University. He was also a Research
Associate of the National Bureau of Economic Research and a Visiting
Scholar at the American Enterprise Institute. Additionally, he was
a Member of the National Cancer Policy Board of the National Academy
of Sciences, Associate Editor of the Journal of Health Economics,
and co-Principal Investigator of the Health and Retirement Study
(HRS), a longitudinal study of the health and economic well-being
of older Americans. From 1998-99, he was Deputy Assistant Secretary
of the Treasury for Economic Policy, where he supervised economic
analysis and policy development on a wide range of domestic policy
issues.
During 2001 and 2002, Dr. McClellan served in the White House.
He was a Member of the President's Council of Economic Advisers,
where he advised on domestic economic issues. He also served during
this time as a senior policy director for health care and related
economic issues for the White House.
Dr. McClellan's research studies have addressed measuring and improving
the quality of health care, the economic and policy factors influencing
medical treatment decisions and health outcomes, estimating the
effects of medical treatments, technological change in health care
and its consequences for health and medical expenditures, and the
relationship between health and economic well-being. He has twice
received the Arrow Award for Outstanding Research in Health Economics.
He earned his MD degree from the Harvard-MIT Division of Health
Sciences and Technology and his PhD in Economics from MIT. He completed
his residency training in internal medicine at Brigham and Women's
Hospital, and he is board-certified in Internal Medicine.
Dr. McClellan is married and has two daughters.
* The post of commissioner was vacant from
Jan. 19, 2001 until November 2002. Bernard A. Schwetz served as
acting principal deputy commissioner from Jan. 21, 2001 until Feb.
24, 2002. At that time, Lester M. Crawford Jr. was appointed deputy
commissioner and he headed the agency until Mark McClellan was appointed
commissioner in November 2002. With Dr. McClellan’s departure
in March 2004, Dr. Crawford was again named to lead FDA, this time
as acting commissioner.
Top of page
![horizontal rule](https://webarchive.library.unt.edu/eot2008/20090118005434im_/http://www.fda.gov/graphics/blkpixel.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090118005434im_/http://www.fda.gov/graphics/dot_clear.gif) |